


 Cite this: *RSC Adv.*, 2020, 10, 4397

Harmane ameliorates obesity through inhibiting lipid accumulation and inducing adipocyte browning

 Yanwen Li,^a Chanjuan Li,^b Jiaqiang Wu,^a Wenfeng Liu,^a Dongli Li^a and Jun Xu^{a*}

 Received 11th November 2019
 Accepted 10th January 2020

DOI: 10.1039/c9ra09383d

rsc.li/rsc-advances

Harmane, a compound derived from *Peganum harmala* L., was discovered as a lipid accumulation inhibitor with our triglyceride (TG) assay. To investigate the molecular mechanism underlying the role of harmane in the prevention of lipid accumulation, a number of biological experiments have been designed to determine if harmane reduces lipid accumulation by suppressing adipogenesis, lipogenesis, and regulating a specific signal transduction pathway. Our experimental data show that harmane inhibits TG accumulation through down-regulating the expression of adipogenic and lipogenic factors, up-regulating adipocyte browning markers and activating the SIRT1-LKB1-AMPK pathway. Therefore, harmane ameliorates obesity through inhibiting lipid accumulation and inducing adipocyte browning.

1. Introduction

Obesity is caused by accumulated white adipose tissues, which store excess energy in the form of triglyceride (TG).¹ The prevalence of overweight and obesity is rising among children and adolescents.² Obesity is a major cause of metabolic disorders such as cardiovascular disease, type 2 diabetes (T2D), and nonalcoholic fatty liver disease. The primary cause of T2D is obesity-driven insulin resistance in white adipose tissue (WAT), and insufficient secretion of insulin.³ These diseases reduce life quality as well as life span.⁴

The differentiation of preadipocytes and the subsequent lipid accumulation in mature adipocytes are well-organized processes accompanied by coordinated genetic changes.⁵ At the early stage of preadipocyte differentiation, the transient expression of CCAAT/enhancer binding protein- β (C/EBP β) induces the expression of C/EBP α and peroxisome proliferator-activated receptor γ (PPAR γ), which promote the formation of mature adipocytes and lipid production.^{6,7} In addition, acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS), and stearoyl coenzyme A desaturase 1 (SCD-1) are rate-limited metabolic enzymes involved in lipogenesis.^{8,9}

Obesity results from greater energy intake than energy expenditure, leading to excessive deposition of WAT in the body.¹⁰ WAT can be induced into brown fat-like adipocytes (BAT), promoting energy expenditure.¹¹ This process is mediated by uncoupling protein 1 (UCP1, the only specific brown adipocyte marker) and activation of oxidative metabolism. BAT

is characterized by multilocular lipid droplet morphology, high mitochondrial content and the expression of a core set of brown fat-specific genes such as UCP1, PPAR α and PGC1 α . These genes and pathways provide a variety of promising therapeutic targets for obesity treatment.¹²

The FDA approved anti-obesity drugs are mainly appetite inhibitors and gastrointestinal lipase inhibitors (orlistat). However, these drugs are not adequate therapies on their own in the long-term, as they have adverse effects in mood changes and gastrointestinal or cardiovascular complications.¹³ Therefore, searching for novel anti-obesity agents is compelling.

Harmane is a compound derived from *Peganum harmala* L. Previous reports demonstrated that harmane had activities against inflammatory, diabetes, and depression.^{14,15} However, the mechanisms of these activities were not articulated.




Fig. 1 Proposed SIRT1-LKB1-AMPK pathway for obesity treatment.

^aSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529000, China. E-mail: junxu@biochemomes.com

^bSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China



Recently, we revealed that harmane inhibited lipid accumulation, but also induced adipocyte browning in 3T3-L1 pre-adipocytes differentiation model.

In order to determine if harmane can be developed into an agent against obesity, we have to investigate the mechanism of action underlying the role of harmane in the prevention of lipid accumulation. Based on the previous reports^{5,9,16} and our experimental data, we hypothesize that harmane might regulate the SIRT1-LKB1-AMPK pathway (Fig. 1). Biological experiments were designed to detect liver kinase B1 (LKB1) and all downstream genes have been regulated by harmane for the obesity treatment.

2. Experimental methods

2.1 3T3-L1 cell differentiation and compound preparation

3T3-L1 pre-adipocytes was cultured in DMEM supplemented with 10% fetal bovine serum (Hyclone, USA), 1% penicillin and streptomycin (Gibco, USA) at 37 °C in 5% CO₂. 3T3-L1 pre-adipocytes was differentiated as previously reported.¹⁷ Two days after confluence (day 0), the medium was changed to a differentiation cocktail mixture containing 0.5 mM 3-isobutyl-1-methylxanthine (Sigma, USA), 100 ng mL⁻¹ dexamethasone (MP, USA), 2 µg mL⁻¹ insulin (Sigma, USA) and 10 ng mL⁻¹ biotin in DMEM with 10% FBS and 1% penicillin and streptomycin for 3 days (day 3). Then, the medium was replaced by 10% FBS/DMEM containing 2 µg mL⁻¹ insulin for another 3 days (day 6). Then, the differentiation medium was changed to culture medium. Harmane was purchased from TargetMol, dissolved in dimethyl sulfoxide (DMSO), and supplemented at indicated concentrations during indicated time course of differentiation. The equal amount of DMSO was used as vehicle.

2.2 TG content assay

Cells were washed three times with PBS (pH 7.4) and then ultrasonically lysed. TG contents were measured using commercial TG assay kit (Jiancheng Bioengineering Institution, Nanjing, China) according to the manufacturer's protocol. Results were presented as the relative TG content compared to the vehicle group.

2.3 Oil Red O (ORO) staining

Cells were fixed with 4% formaldehyde (v/v) for 1 h at room temperature and stained with freshly prepared ORO working solution for 1 h at room temperature and washed three times with distilled water. The plates were scanned using an OLYMPUS CKX41 microscope and camera (OLYMPUS). The ORO working solution was prepared by mixing 6 mL of 0.5% ORO (w/v, Sigma) in isopropanol with 4 mL of distilled water followed by filtration through a 0.22 µm filter (Millipore).

2.4 Cytotoxicity analysis

3T3-L1 and RAW264.7 cells were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). 3T3-L1 and RAW264.7 cells were seeded at the density of 5000 per well into 96-well plates to grow overnight. Then the cells were treated with various concentrations of compounds for 72 hours. Same volume of DMSO is added as vehicle control. 0.5 mg mL⁻¹ MTT solution

was added to each well and incubated for 4 h, after which 150 µL DMSO was added to each well. The absorbance of wells was recorded at 492 nm after 10 min of shaking. The vitality percentage was calculated as $(A_{\text{compound}} - A_{\text{blank}})/(A_{\text{vehicle}} - A_{\text{blank}}) \times 100\%$. The viability of vehicle control is defined as 100%.

2.5 Determination of mitochondrial DNA copy numbers

Mitochondrial DNA (mtDNA) copy numbers was achieved by qPCR. Briefly, DNA was extracted using Sangon Biotech kit. The copy numbers of nuclear DNA (nDNA) and mtDNA were assessed by qPCR using primers targeted toward the cytochrome B gene (for mtDNA) and 18S rRNA (for nDNA).

2.6 Real-time qPCR

Total RNA was isolated using RNAiso plus (Takara, Dalian, China) according to the manufacturer's protocol. Total RNA (1 µg) was converted to cDNA using ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan) according to the manufacturer's protocol. cDNA and SYBR Green were used to amplify specific target genes by Real-time PCR Master Mix (Toyobo, Osaka, Japan). The sequence of primers was described in this table.

Gene	Forward primer (5'-3')	Reversed primer (5'-3')
PPAR γ	TGCTGTTATGGGT GAAACTCTG	GAAATCAACTGT GGTAAAGGGC
C/EBP α	AGTCGGTGGACAAG AACAGCAAC	CGGTCAATTGT CACTGGTCAACTC
C/EBP β	ACCGGGTTTCGG GACTTGA	CCCGCAGGAA CATCTTTAAGTGA
FAS	ATTGGCTCCACCA AATCCAAC	CCCATGCTCC AGGGATAACAG
SCD1	TGTTTCGTTGCCA CTTCTTG	GCTAATGTTT TTGTACATAAGGAC
ACC1	AGGATTGCTGTT TCTCAGAGCTT	CAGGATCTACC CAGGCCACAT
AP2	GTCACCATCCGGTC AGAGAGTAC	TCGTCTGCGGT GATTTCATC
Cyto b	GGCTACGTCCTTC CATGAGG	TGGGATGGCTGA TAGGAGGT
18S rRNA	AACTTTCGATGG TAGTCGC	TTCCTTGATGT GGTAGCC
β -Actin	TGGAATCCTGT GGCATCCATGAAA	TAAAACGCAGCTCAG TAACAGTCC

2.7 Western blotting

The cell lysates were prepared with RIPA lysis buffer containing protease inhibitor cocktail (Beyotime, Shanghai, China) and phosphatase inhibitor (Beyotime, Shanghai, China). Protein concentrations were determined using Pierce™ Rapid Gold BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, USA). Protein samples were denatured in SDS buffer and then subjected to SDS-PAGE and blotted onto polyvinylidene difluoride (PVDF) membrane (Millipore, Darmstadt, Germany). The membranes were blocked using 5% (w/v) skim milk in TBST (Tris-buffered saline containing 0.1% (v/v) Tween 20) for 2 h and then incubated with primary antibodies overnight at 4 °C. After three times washing in TBST, the membranes were incubated







Fig. 2 3T3-L1 cell-based assay results for harmane as a lipid-lowering agent. (A) Harmane structure. (B) The cytotoxicity of harmane on 3T3-L1 adipocytes and RAW264.7 cells. The cells were treated with harmane in five different concentrations for 72 hours. (C) The TG inhibitory effects of harmane on 3T3-L1 cells during days 0–6. (D) The harmane TG inhibitions were measured in Oil Red O (ORO) staining experiments. The pictures were captured in the resolution of 10×40 . (E) Harmane administration time spans. (F and G) Harmane inhibits adipogenesis and lipogenesis within indicated time spans. Harmane was dissolved in DMSO. Control: undifferentiated 3T3-L1 cells. Vehicle: differentiated 3T3-L1 cells treated with equal amount of DMSO. Data are presented as the mean \pm SEM of 3 independent experiments. $###p < 0.001$ vs. control. $**p < 0.01$ vs. vehicle, $***p < 0.001$ vs. vehicle.






Fig. 3 Harmane reduced the mRNA and protein levels of adipogenic and lipogenic factors in 3T3-L1 cells. (A) Harmane reduces the expression of adipogenic factors in mRNA levels, C/EBP β (1 day treatment, from day 0 to day 1), C/EBP α , PPAR γ and AP2 (3 days treatment, from day 0 to day 3) in mRNA levels. (B–D) Harmane inhibits the expression of lipogenic factors in mRNA and protein levels (6 days treatment, from day 0 to day 6). (E) Harmane inhibits the expression of lipogenic factors in 3T3-L1 cells during days 6–9. MDI: differentiation cocktail. All the fold changes in expression were calculated relative to vehicle. Control: undifferentiated cells. Vehicle: differentiated cells treated with equal amount of DMSO. All data are expressed as the mean \pm SEM of 3 independent experiments. ### p < 0.001 vs. control group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle.



with corresponding secondary antibodies at rt for 1 h. Immunoreactive signals were detected using enhanced chemiluminescence reagents with Chemiluminescence imager (Tanon 5200, Shanghai, China). Densitometry analysis was performed using Quantity One Software (Bio-Rad Laboratories, USA). Antibodies used including phospho (Thr172)- and total-AMPK α (Cell Signaling, Danvers, USA), ACC1 (Cell Signaling, Danvers, USA), FAS (Cell Signaling, Danvers, USA), SCD-1 (Cell Signaling, Danvers, USA), α -Tubulin (Sigma, St. Louis, USA), phospho (Ser428)-LKB1 (Cell Signaling, Danvers, USA), SIRT1 (Cell Signaling, Danvers, USA), PCG-1 α (Cell Signaling, Danvers, USA), UCP1 (Cell Signaling, Danvers, USA), PPAR α (Abcam, UK), GAPDH (Bioworld, China).

2.8 Statistical analysis

All data are expressed as the mean \pm SEM. Data between two groups were analyzed by Student's *t*-test using Graphpad Prism (Graphpad Software Inc, California, USA). The significant difference was statistically analyzed using one-way ANOVA

followed by Tukey's HSD *post hoc* test. Statistical significance was set at $P < 0.05$.

3. Results

3.1 Harmane is a lipid-lowering agent

Harmane is not toxic, its effect on cell viability in 3T3-L1 adipocytes and RAW264.7 cells were measured *via* MTT assay as shown in Fig. 2B. Harmane was evaluated with 3T3-L1 cell model¹⁸ for the lipid-lowering activity. As shown in Fig. 2C, harmane decreases lipid accumulation in 3T3-L1 adipocytes in a dose-dependent manner. The lipid inhibitory effects of harmane were also confirmed by ORO staining experiments (Fig. 2D).

To determine whether harmane reduced lipid accumulation by suppressing adipogenesis and/or lipogenesis, we treated 3T3-L1 cells with 10 μ M harmane in various periods, that is, days 0 to 3, 3 to 6, 6 to 9, 0 to 6, 3 to 9, and 0 to 9, which represent different stages of 3T3-L1 differentiation (Fig. 2E). On day 9, the




Fig. 4 Harmane decreases lipid accumulation through inducing adipocyte browning in 3T3-L1 cells. 3T3-L1 pre-adipocytes were treated with differentiation cocktail with or without harmane at indicated concentrations for 6 days. Then the cells were harvested for further analysis. (A) Effects of harmane on the ratio of mtDNA/nDNA. (B and C) Effects of harmane on the expression of proteins related to the browning in 3T3-L1 cells. MDI: differentiation cocktail. Control: undifferentiated cells. Vehicle: differentiated cells treated with equal amount of DMSO. All the fold changes in expression were calculated relative to vehicle. All data are expressed as the mean \pm SEM of 3 independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. vehicle.



TG content was measured by TG assay, representative images were captured. Our results demonstrated that harmane reduced TG content at all the stage of adipocyte differentiation and lipid accumulation (Fig. 2F and G).

3.2 Harmane inhibits lipid accumulation through suppressing adipogenic and lipogenic factors in 3T3-L1 cells

Adipogenesis is regulated by a multiple differentiation factor network, which initiates the process and activates the expression of downstream fatty acid synthesis markers. At the early stage of differentiation (day 0 to day 3), the C/EBP β is rapidly induced to express and subsequently activate C/EBP α expression. C/EBP α can activate the expression of downstream target genes such as PPAR γ and AP2.^{19,20}

To prove the regulation effect of harmane in the differentiation stage, we performed qPCR on 3T3-L1 cells with harmane treatment. Our results demonstrate that harmane decreases the mRNA levels of C/EBP β with the treatment for 1 day. Subsequently, the mRNA levels of PPAR γ , C/EBP α and AP2, were attenuated in a dose-dependent manner with harmane treatment compared to the vehicle (Fig. 3A). These results indicate

that harmane inhibits lipid accumulation by suppressing adipogenic factor expression.

C/EBP α and PPAR γ are the upstream regulators of the lipogenic process, which regulates fatty acid synthesis through activating the expression of genes related with lipid metabolism such as ACC1, FAS and SCD-1.²¹ Correspondingly, the levels of fatty acid synthesis related mRNAs were decreased dose-dependently by the treatments of harmane for 6 days (Fig. 3B). Furthermore, harmane strongly downregulated lipogenesis-related markers protein expression with 6 days treatment, supporting the qPCR data (Fig. 3C and D). These results indicate that harmane inhibits lipid accumulation by suppressing lipogenic factor expression.

3.3 Harmane decreases lipid accumulation through inducing adipocyte browning in 3T3-L1 cells

BAT is a key site of heat production in mammals that has been considered an attractive target to promote weight loss.²² UCP1 is responsible for the unique function of brown adipose tissue. PPAR α may coordinate expression of fatty acid oxidation enzymes with expression of UCP1. Besides, PGC-1 α causes an




Fig. 5 Harmane activates SIRT1-LKB1-AMPK pathway. 3T3-L1 pre-adipocytes were treated with differentiation cocktail with harmane at indicated concentrations for 4 hours. (A) Harmane dose-dependently activates SIRT1-LKB1-AMPK pathway. (B) The bar-charts to show harmane dose-dependently activates. MDI: differentiation cocktail. Control: undifferentiated cells. Vehicle: differentiated cells treated with equal amount of DMSO. All the fold changes in expression were calculated relative to vehicle. All data are expressed as the mean \pm SEM of 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle.



increase expression for UCP1.^{23,24} To prove the browning effect of harmine in the differentiation stage, we performed WB on 3T3-L1 cells with harmine treatment. Consistently, treatment with harmine increased the copy numbers of mtDNA (Fig. 4A), mitochondrial transcription factor PGC-1 α and PPAR α . Furthermore, there was a robust increase in the expression levels of UCP1 at translational levels (Fig. 4B and C). These results suggest that harmine decrease lipid accumulation and induce browning in 3T3-L1 cells, involved in the anti-obesity effect.

3.4 Harmine decreases lipid accumulation through activating SIRT1-LKB1-AMPK pathway

AMP-activated protein kinase (AMPK) is a significant player in regulating energy metabolism. Activated AMPK was reported to be upstream mechanism of the inhibition of adipogenesis and lipogenesis.^{9,25} AMPK also enhances SIRT1 activity, resulting in the modulation of the activity of downstream SIRT1 targets that include the PGC-1 α .¹⁶ LKB1 is a key kinase controlling AMPK activity and phosphorylation of AMPK.²⁶ As shown in Fig. 5A and B, activation of AMPK and LKB1 was observed with harmine treatment in a dose-dependent manner. Besides, the activity of SIRT1 is significantly improved. These results demonstrate that harmine decrease TG accumulation with the activation of the SIRT1-LKB1-AMPK pathway.

4. Conclusion

Harmine, a natural product derived from *Peganum harmala* L., is a lipid accumulation inhibitor. This study proves that harmine inhibits TG accumulation through down-regulating the expression of adipogenic and lipogenic factors, up-regulating adipocyte browning markers and activating SIRT1-LKB1-AMPK pathway. Hence, harmine can be a lead to be developed into a therapeutic agent against obesity and related metabolic diseases.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work has been funded by the National Natural Science Foundation of China (No. 81870608), the Science and technology Planning Project of Guangdong Province (No. 2016A020217002), the National Key R&D Program of China (2017YFB0203403) and Science and Technology of Jiangmen (No. 2016350100170008351, 2018110100330005446).

References

1 D. W. Haslam and W. P. James, *Lancet*, 2005, **366**, 1197–1209.

- 2 M. Ng, T. Fleming, M. Robinson, B. Thomson, N. Graetz, C. Margono, E. C. Mullany, S. Biryukov, C. Abbafati, S. F. Abera, *et al.*, *Lancet*, 2014, **384**, 766–781.
- 3 M. Shimabukuro, Y.-T. Zhou, M. Levi and R. H. Unger, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 2498–2502.
- 4 S. J. Olshansky, D. J. Passaro, R. C. Hershov, J. Layden, B. A. Carnes, J. Brody, L. Hayflick, R. N. Butler, D. B. Allison and D. S. Ludwig, *N. Engl. J. Med.*, 2005, **352**, 1138–1145.
- 5 E. D. Rosen and O. A. MacDougald, *Nat. Rev. Mol. Cell Biol.*, 2006, **7**, 885–896.
- 6 F. M. Gregoire, C. A. Smas and H. S. Sul, *Physiol. Rev.*, 1998, **78**, 783–809.
- 7 M. Ahmadian, J. M. Suh, N. Hah, C. Liddle, A. R. Atkins, M. Downes and R. M. Evans, *Nat. Med.*, 2013, **19**, 557–566.
- 8 E. D. Rosen, C. J. Walkey, P. Puigserver and B. M. Spiegelman, *Genes Dev.*, 2000, **14**, 1293–1307.
- 9 B. B. Zhang, G. Zhou and C. Li, *Cell Metab.*, 2009, **9**, 407–416.
- 10 Y.-H. Tseng, A. M. Cypess and C. R. Kahn, *Nat. Rev. Drug Discovery*, 2010, **9**, 465–481.
- 11 M. Rosenwald, A. Perdikari, T. Rulicke and C. Wolfrum, *Nat. Cell Biol.*, 2013, **15**, 659–667.
- 12 M. Harms and P. Seale, *Nat. Med.*, 2013, **19**, 1252–1263.
- 13 R. S. Padwal and S. R. Majumdar, *Lancet*, 2007, **369**, 71–77.
- 14 H. Khan, S. Patel and M. A. Kamal, *Curr. Drug Metab.*, 2017, **18**, 853–857.
- 15 E. J. Cooper, A. L. Hudson, C. A. Parker and N. G. Morgan, *Eur. J. Pharmacol.*, 2003, **482**, 189–196.
- 16 C. Canto, Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. Puigserver and J. Auwerx, *Nature*, 2009, **458**, 1056–1060.
- 17 C. Li, B. Cheng, S. Fang, H. Zhou, Q. Gu and J. Xu, *Eur. J. Med. Chem.*, 2018, **143**, 114–122.
- 18 X. Y. Zeng, X. Zhou, J. Xu, S. M. Chan, C. L. Xue, J. C. Molero and J. M. Ye, *Biochem. Pharmacol.*, 2012, **84**, 830–837.
- 19 T. Hishida, M. Nishizuka, S. Osada and M. Imagawa, *Biochimie*, 2009, **91**, 654–657.
- 20 E. Chang and C. Y. Kim, *Molecules*, 2019, **24**(6), 1157.
- 21 M. M. Mihaylova and R. J. Shaw, *Nat. Cell Biol.*, 2011, **13**, 1016–1023.
- 22 B. Cannon and J. Nedergaard, *Physiol. Rev.*, 2004, **84**, 277–359.
- 23 M. J. Barbera, A. Schluter, N. Pedraza, P. Iglesias, F. Villarroya and M. Giralt, *J. Biol. Chem.*, 2001, **276**, 1486–1493.
- 24 Z. Wu, P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cinti, B. Lowell, R. C. Scarpulla, *et al.*, *Cell*, 1999, **98**, 115–124.
- 25 B. Viollet, B. Guigas, J. Leclerc, S. Hébrard, L. Lantier, R. Mounier, F. Andreelli and M. Foretz, *Crit. Rev. Biochem. Mol. Biol.*, 2010, **196**, 81–98.
- 26 S. A. Hawley, J. Boudeau, J. L. Reid, K. J. Mustard, L. Udd, T. P. Makela, D. R. Alessi and D. G. Hardie, *J. Biol.*, 2003, **2**, 28.

